SAN DIEGO, July 19, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, and Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator, and developer of high-quality, sustainable real estate and technica...
SAN DIEGO, July 11, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company was recently named as one of the San Diego Business Journal's, 2012 Best Places to Work in San Diego. The county-wide...
SAN DIEGO, May 31, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Jeff Black, Senior Vice President and Chief Financial Officer, will present at the upcoming Ardour Capital Energy Technology Confer...
SAN DIEGO, May 10, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported operating highlights and financial results for the first quarter ended March 31, 2012.
"The first quarter was a turning point for...
SAN DIEGO, May 7, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that Janet Roemer, Executive Vice President and Chief Operating Officer, will present at the upcoming Deutsche Bank Clean Tech, Utilities...
SAN DIEGO, May 3, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2012 first quarter financial results on Thursday, May 10, 2012 after market close. In conjunction with the release, ...
SAN DIEGO, April 24, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company is a sponsor and scheduled presenter at the upcoming 2012 BIO World Congress on Industrial Biotechnology and Bioproce...
SAN DIEGO, April 2, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the repurchase of all its outstanding 5.5% Convertible Senior Notes due 2027 (the "Notes"). The tender offer period for the put option ...
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced it has closed a transaction with DSM Food Specialties B.V., a business group of Royal DSM, in which Verenium has sold to DSM its Oilse...
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it is notifying holders of the $34,851,000 outstanding principal amount of its 5.5% Convertible Senior Notes due 2027 that it will...
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported financial results for the fourth quarter and year ended December 31, 2011.
"2011 was an important year for Verenium. The growth in ...
SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 fourth quarter and year-end financial results on Monday, March 5, 2012 at 8:00 a.m. ET. In conjunction with t...
SAN DIEGO, Jan. 30, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced an agreement with Tate & Lyle for the use of one of its proprietary enzyme products in the development of novel food ingredients.
...
ST. LOUIS and SAN DIEGO, Jan. 23, 2012 /PRNewswire/ -- Novus International Inc., a leading manufacturer of animal and human nutrition and health products and Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the selection of a...
SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the introduction of VEREFLOW™ alpha-amylase, a unique enzyme for the removal of filter cake in drilling operations. This high per...
SAN DIEGO, Dec. 7, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that sales of its Purifine® phospholipase C (PLC) enzyme product will now also be targeted for use in pretreatment of oil for biodi...
SAN DIEGO, Nov. 23, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that James Levine, Executive Vice President and Chief Financial Officer, will present at the upcoming Baird 2011 Clean Technology Confe...
SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the third quarter and nine months ended September 30, 2011.
"We have...
SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 third quarter financial results on Thursday, November 10, 2011 after market close. In conjunction with the rel...
SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company developing and commercializing high-performance enzymes, today announced that it has entered into an agreement with Comerica Bank and the Export-Import Bank of the United States ("Ex-Im Bank") for two 18-month, secured revolving ...
Delicious
Digg
Facebook
LinkedIn
Twitter
